Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy – Neurologist, Nursing and Patient Perspectives
暂无分享,去创建一个
R. Lewis | V. Bril | Jeffrey A. Allen | T. Harbo | H. Katzberg | D. Grosse-Kreul | M. Bullock | J. B. Smith
[1] D. Vinh,et al. Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings , 2018, Expert opinion on drug delivery.
[2] D. Cornblath,et al. IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. , 2018, Immunotherapy.
[3] G. Tedeschi,et al. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin , 2018, Clinical Neurophysiology.
[4] G. L. Masson,et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial , 2018, The Lancet Neurology.
[5] T. Harbo,et al. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs , 2017, Journal of the Neurological Sciences.
[6] L. Sposato,et al. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta‐analysis , 2017, Muscle & nerve.
[7] L. Lopiano,et al. Subcutaneous vs. intravenous immunoglobulin in CIDP: pharmacokinetic and clinical response , 2016, Journal of the peripheral nervous system : JPNS.
[8] J. Lawo,et al. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency , 2016, Journal of Clinical Immunology.
[9] J. Jakobsen,et al. Headache and Nausea after Treatment with High‐Dose Subcutaneous versus Intravenous Immunoglobulin , 2015, Basic & Clinical Pharmacology & Toxicology.
[10] R. Hughes,et al. Chronic in fl ammatory demyelinating polyradiculoneuropathy: from pathology to phenotype , 2022 .
[11] A N N Gardulf,et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease , 2015, Clinical and experimental immunology.
[12] R. Hadden,et al. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction , 2015, Therapeutic advances in neurological disorders.
[13] J. Jakobsen,et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy , 2014, European journal of neurology.
[14] W. Robberecht,et al. Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) , 2013, Journal of the peripheral nervous system : JPNS.
[15] H. Hartung,et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG – the ICE study , 2013, European journal of neurology.
[16] L. Lopiano,et al. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies , 2012, Journal of the peripheral nervous system : JPNS.
[17] R. Nelson,et al. Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency , 2011, Clinical pharmacokinetics.
[18] J. Pollard,et al. CIDP – the relevance of recent advances in Schwann cell/axonal neurobiology , 2011, Journal of the peripheral nervous system : JPNS.
[19] M. Bakkers,et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies , 2011, Neurology.
[20] S. Spector,et al. Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency , 2010, Journal of Clinical Immunology.
[21] J. Pollard,et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision , 2010, European journal of neurology.
[22] R. Hughes,et al. Clinical applications of intravenous immunoglobulins in neurology , 2009, Clinical and experimental immunology.
[23] R. Hughes. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial , 2009, Expert review of neurotherapeutics.
[24] F. Bonilla. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. , 2008, Immunology and allergy clinics of North America.
[25] M. Berger. Subcutaneous administration of IgG. , 2008, Immunology and allergy clinics of North America.
[26] F. Käsermann,et al. Investigations of prion and virus safety of a new liquid IVIG product. , 2008, Biologicals : journal of the International Association of Biological Standardization.
[27] H. Hartung,et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial , 2008, The Lancet Neurology.
[28] M. Berger. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. , 2004, Clinical immunology.
[29] G. Comi,et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy , 2001, Annals of neurology.